Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 22
Filtrar
Mais filtros

País/Região como assunto
Intervalo de ano de publicação
1.
Circ Cardiovasc Imaging ; 17(2): e015496, 2024 02.
Artigo em Inglês | MEDLINE | ID: mdl-38377236

RESUMO

Achieving optimal cardiovascular health in rural populations can be challenging for several reasons including decreased access to care with limited availability of imaging modalities, specialist physicians, and other important health care team members. Therefore, innovative solutions are needed to optimize health care and address cardiovascular health disparities in rural areas. Mobile examination units can bring imaging technology to underserved or remote communities with limited access to health care services. Mobile examination units can be equipped with a wide array of assessment tools and multiple imaging modalities such as computed tomography scanning and echocardiography. The detailed structural assessment of cardiovascular and lung pathology, as well as the detection of extracardiac pathology afforded by computed tomography imaging combined with the functional and hemodynamic assessments acquired by echocardiography, yield deep phenotyping of heart and lung disease for populations historically underrepresented in epidemiological studies. Moreover, by bringing the mobile examination unit to local communities, innovative approaches are now possible including engagement with local professionals to perform these imaging assessments, thereby augmenting local expertise and experience. However, several challenges exist before mobile examination unit-based examinations can be effectively integrated into the rural health care setting including standardizing acquisition protocols, maintaining consistent image quality, and addressing ethical and privacy considerations. Herein, we discuss the potential importance of cardiac multimodality imaging to improve cardiovascular health in rural regions, outline the emerging experience in this field, highlight important current challenges, and offer solutions based on our experience in the RURAL (Risk Underlying Rural Areas Longitudinal) cohort study.


Assuntos
Imagem Multimodal , População Rural , Humanos , Estudos Longitudinais , Estudos de Coortes
2.
AIDS ; 36(14): 1997-2003, 2022 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-35876637

RESUMO

OBJECTIVE: To characterize diet quality across a global cohort of people with HIV (PWH). DESIGN: Cross-sectional analysis. METHODS: Leveraging REPRIEVE data from baseline across five Global Burden of Disease (GBD) regions, we analyzed participant responses to the Rapid Eating Assessment for Participants questionnaire. An overall diet quality score and scores for specific diet components were generated. Higher scores indicate better diet quality. RESULTS: Among 7736 participants (median age 50 years, 30% women, median BMI 25.8 kg/m 2 ) overall diet quality score (max score 30) was optimal in 13% of participants and good, suboptimal or poor in 45%, 38%, and 4% of participants, respectively; saturated fat score (max score 18) was good, suboptimal, or poor in 38%, 40%, or 7% of participants, respectively. Diet quality scores differed across GBD region with the highest scores reported in the South Asia region [median 23 (21-25)] and lowest in the sub-Saharan Africa region [median 15 (12-18)]; 61% of participants in the South Asia region reported optimal diet quality compared with only 6% in the sub-Saharan Africa region. Higher atherosclerotic cardiovascular risk scores were seen with worsening diet quality. CONCLUSION: Among PWH eligible for primary CVD prevention, diet quality was suboptimal or poor for almost half of participants, and there were substantial variations in diet quality reported by GBD region. TRIAL REGISTRATION: NCT02344290.


Assuntos
Doenças Cardiovasculares , Infecções por HIV , Adulto , Humanos , Feminino , Pessoa de Meia-Idade , Masculino , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/prevenção & controle , Estudos Transversais , Infecções por HIV/complicações , Carga Global da Doença , Dieta
3.
BMC Health Serv Res ; 22(1): 315, 2022 Mar 07.
Artigo em Inglês | MEDLINE | ID: mdl-35255913

RESUMO

BACKGROUND: Health system approaches to improve hypertension control require an effective referral network. A national referral strategy exists in Kenya; however, a number of barriers to referral completion persist. This paper is a baseline assessment of a hypertension referral network for a cluster-randomized trial to improve hypertension control and reduce cardiovascular disease risk. METHODS: We used sociometric network analysis to understand the relationships between providers within a network of nine geographic clusters in western Kenya, including primary, secondary, and tertiary care facilities. We conducted a survey which asked providers to nominate individuals and facilities to which they refer patients with controlled and uncontrolled hypertension. Degree centrality measures were used to identify providers in prominent positions, while mixed-effect regression models were used to determine provider characteristics related to the likelihood of receiving referrals. We calculated core-periphery correlation scores (CP) for each cluster (ideal CP score = 1.0). RESULTS: We surveyed 152 providers (physicians, nurses, medical officers, and clinical officers), range 10-36 per cluster. Median number of hypertensive patients seen per month was 40 (range 1-600). While 97% of providers reported referring patients up to a more specialized health facility, only 55% reported referring down to lower level facilities. Individuals were more likely to receive a referral if they had higher level of training, worked at a higher level facility, were male, or had more job experience. CP scores for provider networks range from 0.335 to 0.693, while the CP scores for the facility networks range from 0.707 to 0.949. CONCLUSIONS: This analysis highlights several points of weakness in this referral network including cluster variability, poor provider linkages, and the lack of down referrals. Facility networks were stronger than provider networks. These shortcomings represent opportunities to focus interventions to improve referral networks for hypertension. TRIAL REGISTRATION: Trial Registered on ClinicalTrials.gov NCT03543787 , June 1, 2018.


Assuntos
Hipertensão , Encaminhamento e Consulta , Programas Governamentais , Humanos , Hipertensão/epidemiologia , Hipertensão/terapia , Quênia , Masculino , Assistência Médica
4.
Afr J Emerg Med ; 11(4): 404-409, 2021 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-34703731

RESUMO

INTRODUCTION: Data describing atrial fibrillation (AF) care in emergency centres (ECs) in sub-Saharan Africa is lacking. We sought to describe the prevalence and outcomes of AF in a Tanzanian EC. METHODS: In a prospective, observational study, adults presenting with chest pain or shortness of breath to a Tanzanian EC were enrolled from January through October 2019. Participants underwent electrocardiogram testing which were reviewed by two independent physician judges to determine presence of AF. Participants were asked about their medical history and medication use at enrollment, and a follow-up questionnaire was administered via telephone thirty days later to assess mortality, interim stroke, and medication use. RESULTS: Of 681 enrolled patients, 53 (7.8%) had AF. The mean age of participants with AF was 68.1, with a standard deviation (sd) of 21.1 years, and 23 of the 53 (43.4%) being male. On presentation, none of the participants found to have AF reported a previous history of AF. The median CHADS-VASC score among participants was 4 with an interquartile range (IQR) of 2-4. No participants were taking an anticoagulant at baseline. On index presentation, 49 (92.5%) participants with AF were hospitalised with 52 (98.1%) participants completing 30-day follow-up. 18 (34%) participants died, and 5 (9.6%) suffered a stroke. Of the surviving 31 participants with AF and a CHADS-VASC score ≥ 2, none were taking other anti-coagulants at 30 days. Compared to participants without AF, participants with AF were more likely to be hospitalised (OR 5.25, 95% CI 2.10-17.95, p < 0.001), more likely to die within thirty days (OR 1.93, 95% CI 1.03-3.50, p = 0.031), and more likely to suffer a stroke within thirty days (OR 5.91, 95% CI 1.76-17.28, p < 0.001). DISCUSSION: AF is common in a Tanzanian EC, with thirty-day mortality being high, but use of evidence-based therapies is rare. There is an opportunity to improve AF care and outcomes in Tanzania.

5.
PLoS One ; 16(6): e0248496, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34097700

RESUMO

BACKGROUND: Non-communicable diseases (NCDs) are the leading cause of mortality in the world, and innovative approaches to NCD care delivery are being actively developed and evaluated. Combining the group-based experience of microfinance and group medical visits is a novel approach to NCD care delivery. However, the contextual factors, facilitators, and barriers impacting wide-scale implementation of these approaches within a low- and middle-income country setting are not well known. METHODS: Two types of qualitative group discussion were conducted: 1) mabaraza (singular, baraza), a traditional East African community gathering used to discuss and exchange information in large group settings; and 2) focus group discussions (FGDs) among rural clinicians, community health workers, microfinance group members, and patients with NCDs. Trained research staff members led the discussions using structured question guides. Content analysis was performed with NVivo using deductive and inductive codes that were then grouped into themes. RESULTS: We conducted 5 mabaraza and 16 FGDs. A total of 205 individuals (113 men and 92 women) participated in the mabaraza, while 162 individuals (57 men and 105 women) participated in the FGDs. In the context of poverty and previous experiences with the health system, participants described challenges to NCD care across three themes: 1) stigma of chronic disease, 2) earned skepticism of the health system, and 3) socio-economic fragility. However, they also outlined windows of opportunity and facilitators of group medical visits and microfinance to address those challenges. DISCUSSION: Our qualitative study revealed actionable factors that could impact the success of implementation of group medical visits and microfinance initiatives for NCD care. While several challenges were highlighted, participants also described opportunities to address and mitigate the impact of these factors. We anticipate that our approach and analysis provides new insights and methodological techniques that will be relevant to other low-resource settings worldwide.


Assuntos
Atitude Frente a Saúde/etnologia , Doença Crônica/psicologia , Acessibilidade aos Serviços de Saúde/estatística & dados numéricos , Doença Crônica/epidemiologia , Agentes Comunitários de Saúde/psicologia , Atenção à Saúde/tendências , Feminino , Grupos Focais , Programas Governamentais/tendências , Acessibilidade aos Serviços de Saúde/tendências , Humanos , Quênia , Masculino , Assistência Médica , Doenças não Transmissíveis/epidemiologia , Doenças não Transmissíveis/prevenção & controle , Pesquisa Qualitativa , População Rural/tendências , Estigma Social , Participação dos Interessados/psicologia
6.
Glob Heart ; 16(1): 4, 2021 01 18.
Artigo em Inglês | MEDLINE | ID: mdl-33598384

RESUMO

Background: Cardiovascular disease (CVD) is the leading cause of death and disability worldwide. Health research is crucial to managing disease burden. Previous work has highlighted marked discrepancies in research output and disease burden between high-income countries (HICs) and low- and lower-middle-income countries (LI-LMICs) and there is little data to understand whether this gap has bridged in recent years. We conducted a global, country level bibliometric analysis of CVD publications with respect to trends in disease burden and county development indicators. Methods: A search filter with a precision and recall of 0.92 and 0.91 respectively was developed to extract cardiovascular publications from the Web of Science (WOS) for the years 2008-2017. Data for disease burden and country development indicators were extracted from the Global Burden of Disease and the World Bank database respectively. Results: Our search revealed 847,708 CVD publications for the period 2008-17, with a 43.4% increase over the decade. HICs contributed 81.1% of the global CVD research output and accounted for 8.1% and 8.5% of global CVD DALY losses deaths respectively. LI-LMICs contributed 2.8% of the total output and accounted for 59.5% and 57.1% global CVD DALY losses and death rates. Conclusions: A glaring disparity in research output and disease burden persists. While LI-LMICs contribute to the majority of DALYs and mortality from CVD globally, their contribution to research output remains the lowest. These data call on national health budgets and international funding support to allocate funds to strengthen research capacity and translational research to impact CVD burden in LI-LMICs.


Assuntos
Doenças Cardiovasculares , Pessoas com Deficiência , Bibliometria , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/terapia , Efeitos Psicossociais da Doença , Saúde Global , Humanos , Pobreza
7.
Lancet HIV ; 7(4): e279-e293, 2020 04.
Artigo em Inglês | MEDLINE | ID: mdl-32243826

RESUMO

HIV-related cardiovascular disease research is predominantly from Europe and North America. Of the estimated 37·9 million people living with HIV worldwide, 25·6 million live in sub-Saharan Africa. Although mechanisms for HIV-related cardiovascular disease might be the same in all people with HIV, the distribution of cardiovascular disease risk factors varies by geographical location. Sub-Saharan Africa has a younger population, higher prevalence of elevated blood pressure, lower smoking rates, and lower prevalence of elevated cholesterol than western Europe and North America. These variations mean that the profile of cardiovascular disease differs between low-income and high-income countries. Research in, implementation of, and advocacy for risk reduction of cardiovascular disease in the global context of HIV should account for differences in the distribution of traditional cardiovascular disease risk factors (eg, hypertension, smoking), consider non-traditional cardiovascular disease risk factors (eg, access to antiretroviral therapy with more benign cardiovascular disease side effect profiles, indoor air pollution), and encourage the inclusion of relevant risk reduction approaches for cardiovascular disease in HIV-care guidelines. Future research priorities include implementation science to scale up and expand integrated HIV and cardiovascular disease care models, which have shown promise in sub-Saharan Africa; HIV and cardiovascular disease epidemiology and mechanisms in women; and tobacco cessation for people living with HIV.


Assuntos
Doenças Cardiovasculares/epidemiologia , Infecções por HIV/complicações , Doenças Cardiovasculares/economia , Doenças Cardiovasculares/etiologia , Humanos , Pobreza , Prevalência
8.
Prog Cardiovasc Dis ; 63(2): 142-148, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32057785

RESUMO

Despite developments to improve health in the United States, racial and ethnic disparities persist. These disparities have profound impact on the wellbeing of historically marginalized racial and ethnic groups. This narrative review explores disparities by race in people living with cardiovascular disease (CVD) and the Human Immunodeficiency Virus (HIV). We discuss selected common social determinants of health for both of these conditions which include; regional historical policies, incarceration, and neighborhood effects. Data on racial disparities for persons living with comorbid HIV and CVD are lacking. We found few published articles (n = 7) describing racial disparities for persons living with both comorbid HIV and CVD. Efforts to reduce CVD morbidity in historically marginalized racial and ethnic groups with HIV must address participation in clinical research, social determinants of health and translation of research into clinical practice.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Infecções por HIV/tratamento farmacológico , Sobreviventes de Longo Prazo ao HIV , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde/etnologia , Serviços Preventivos de Saúde , Marginalização Social , Populações Vulneráveis , Fármacos Anti-HIV/efeitos adversos , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/etnologia , Comorbidade , Infecções por HIV/diagnóstico , Infecções por HIV/etnologia , Humanos , Prognóstico , Fatores de Proteção , Fatores Raciais , Medição de Risco , Fatores de Risco , Determinantes Sociais da Saúde , Fatores Socioeconômicos , Carga Viral
9.
Prog Cardiovasc Dis ; 63(2): 149-159, 2020.
Artigo em Inglês | MEDLINE | ID: mdl-32035126

RESUMO

As longevity has increased for people living with HIV (PLWH) in the United States and Europe, there has been a concomitant increase in the prevalence of cardiovascular disease (CVD) risk factors and morbidity in this population. Whereas the availability of HIV antiretroviral therapy has resulted in dramatic increases in life expectancy in sub-Saharan Africa (SSA), where over two thirds of PLWH reside, if and how these trends impact the epidemiology of CVD is less clear. In this review, we describe the current state of the science on how both HIV and its treatment impact CVD risk factors and outcomes among PLWH in sub-Saharan Africa, including regional factors (unique to SSA) likely to differentiate these relationships from the global North. We then outline how current regional guidelines address CVD prevention among PLWH and which clinical and structural interventions are best poised to confront the co-epidemics of HIV and CVD in the region. We conclude with a discussion of key research gaps that need to be addressed to optimally develop an actionable public health response.


Assuntos
Fármacos Anti-HIV/uso terapêutico , Doenças Cardiovasculares/prevenção & controle , Infecções por HIV/tratamento farmacológico , Sobreviventes de Longo Prazo ao HIV , Serviços Preventivos de Saúde , África Subsaariana/epidemiologia , Fármacos Anti-HIV/efeitos adversos , Doenças Cardiovasculares/diagnóstico , Doenças Cardiovasculares/epidemiologia , Infecções por HIV/diagnóstico , Infecções por HIV/epidemiologia , Nível de Saúde , Disparidades nos Níveis de Saúde , Disparidades em Assistência à Saúde , Humanos , Expectativa de Vida , Prognóstico , Fatores de Proteção , Medição de Risco , Fatores de Risco , Carga Viral
10.
Trials ; 20(1): 554, 2019 Sep 09.
Artigo em Inglês | MEDLINE | ID: mdl-31500661

RESUMO

BACKGROUND: Hypertension is a major risk factor for cardiovascular disease (CVD), yet treatment and control rates for hypertension are very low in low- and middle-income countries (LMICs). Lack of effective referral networks between different levels of the health system is one factor that threatens the ability to achieve adequate blood pressure control and prevent CVD-related morbidity. Health information technology and peer support are two strategies that have improved care coordination and clinical outcomes for other disease entities in other settings; however, their effectiveness and cost-effectiveness in strengthening referral networks to improve blood pressure control and reduce CVD risk in low-resource settings are unknown. METHODS/DESIGN: We will use the PRECEDE-PROCEED framework to conduct transdisciplinary implementation research, focused on strengthening referral networks for hypertension in western Kenya. We will conduct a baseline needs and contextual assessment using a mixed-methods approach, in order to inform a participatory, community-based design process to fully develop a contextually and culturally appropriate intervention model that combines health information technology and peer support. Subsequently, we will conduct a two-arm cluster randomized trial comparing 1) usual care for referrals vs 2) referral networks strengthened with our intervention. The primary outcome will be one-year change in systolic blood pressure. The key secondary clinical outcome will be CVD risk reduction, and the key secondary implementation outcomes will include referral process metrics such as referral appropriateness and completion rates. We will conduct a mediation analysis to evaluate the influence of changes in referral network characteristics on intervention outcomes, a moderation analysis to evaluate the influence of baseline referral network characteristics on the effectiveness of the intervention, as well as a process evaluation using the Saunders framework. Finally, we will analyze the incremental cost-effectiveness of the intervention relative to usual care, in terms of costs per unit decrease in systolic blood pressure, per percentage change in CVD risk score, and per disability-adjusted life year saved. DISCUSSION: This study will provide evidence for the implementation of innovative strategies for strengthening referral networks to improve hypertension control in LMICs. If effective, it has the potential to be a scalable model for health systems strengthening in other low-resource settings worldwide. TRIAL REGISTRATION: Clinicaltrials.gov, NCT03543787 . Registered on 29 June 2018.


Assuntos
Atenção à Saúde , Hipertensão/tratamento farmacológico , Ensaios Clínicos Controlados Aleatórios como Assunto , Encaminhamento e Consulta , Adulto , Análise por Conglomerados , Análise Custo-Benefício , Humanos , Quênia , Informática Médica , Projetos de Pesquisa
11.
Lancet Gastroenterol Hepatol ; 4(10): 794-804, 2019 10.
Artigo em Inglês | MEDLINE | ID: mdl-31377134

RESUMO

BACKGROUND: More than 70 million people worldwide are estimated to have hepatitis C virus (HCV) infection. Emerging evidence indicates an association between HCV and atherosclerotic cardiovascular disease. We aimed to determine the association between HCV and cardiovascular disease, and estimate the national, regional, and global burden of cardiovascular disease attributable to HCV. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, Ovid Global Health, and Web of Science databases from inception to May 9, 2018, without language restrictions, for longitudinal studies that evaluated the risk ratio (RR) of cardiovascular disease in people with HCV compared with those without HCV. Two investigators independently reviewed and extracted data from published reports. The main outcome was cardiovascular disease, defined as hospital admission with, or mortality from, acute myocardial infarction or stroke. We calculated the pooled RR of cardiovascular disease associated with HCV using a random-effects model. Additionally, we calculated the population attributable fraction and disability-adjusted life-years (DALYs) from HCV-associated cardiovascular disease at the national, regional, and global level. We also used age-stratified and sex-stratified HCV prevalence estimates and cardiovascular DALYs for 100 countries to estimate country-level burden associated with HCV. This study is registered with PROSPERO, number CRD42018091857. FINDINGS: Our search identified 16 639 records, of which 36 studies were included for analysis, including 341 739 people with HCV. The pooled RR for cardiovascular disease was 1·28 (95% CI 1·18-1·39). Globally, 1·5 million (95% CI 0·9-2·1) DALYs per year were lost due to HCV-associated cardiovascular disease. Low-income and middle-income countries had the highest disease burden with south Asian, eastern European, north African, and Middle Eastern regions accounting for two-thirds of all HCV-associated cardiovascular DALYs. INTERPRETATION: HCV infection is associated with an increased risk of cardiovascular disease. The global burden of cardiovascular disease associated with HCV infection was responsible for 1·5 million DALYs, with the highest burden in low-income and middle-income countries. FUNDING: British Heart Foundation and Wellcome Trust.


Assuntos
Aterosclerose/virologia , Hepatite C Crônica/complicações , Aterosclerose/epidemiologia , Carga Global da Doença/estatística & dados numéricos , Hepatite C Crônica/epidemiologia , Humanos , Prevalência , Anos de Vida Ajustados por Qualidade de Vida , Medição de Risco/métodos
12.
Glob Heart ; 14(2): 173-179, 2019 06.
Artigo em Inglês | MEDLINE | ID: mdl-31324372

RESUMO

BACKGROUND: Ineffective referral networks in low- and middle-income countries hinders access to evidence-based therapies by hypertensive patients, leading to high cardiovascular mortality and morbidity. The STRENGTHS (Strengthening Referral Networks for Management of Hypertension Across Health Systems) study evaluates strategies to improve referral processes utilizing the International Association of Public Participation framework to engage stakeholders. OBJECTIVES: This study sought to identify and engage key stakeholders involved in referral of patients in the Ministry of Health, western Kenya. METHODS: Key stakeholders involved in policy formulation, provision, or consumption of public health care service were mapped out and contacted by phone, letters, and emissaries to schedule meetings, explain research objectives, and obtain feedback. RESULTS: Key stakeholders identified were the Ministry of Health, the Academic Model Providing Access to Healthcare, health professionals, communities and their leadership, and patients. Engaging them resulted in permission to contact research in their areas of jurisdiction and enabled collaboration in updating care protocols with emphasis on timely and appropriate referrals. CONCLUSIONS: Early stakeholder identification and engagement using the International Association of Public Participation model eased explanation of research objectives, building consensus, and shaping the interventions to improve the referral process.


Assuntos
Atenção à Saúde/normas , Gerenciamento Clínico , Guias como Assunto , Pessoal de Saúde/normas , Hipertensão/prevenção & controle , Liderança , Participação dos Interessados , Humanos , Hipertensão/epidemiologia , Quênia/epidemiologia , Prevalência
13.
Curr Opin HIV AIDS ; 12(6): 579-584, 2017 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-28799999

RESUMO

PURPOSE OF REVIEW: The current article addresses crucial issues in identifying risk of cardiovascular disease (CVD) in people living with HIV in low-income and middle-income countries (LMICs). These issues are in need of urgent attention to advance our knowledge and inform actions to mitigate CVD in this population. We address CVDs in adults living with HIV as well as the unique aspects pertaining to children living with HIV (CLHIV), a group sorely under-represented in this field. RECENT FINDINGS: CVDs affecting adults such as hypertension, dyslipidemia, coronary artery disease, and heart failure, in addition to myocardial dysfunction, vascular diseases, and autoimmune phenomena are also being reported in CLHIV. In addition to the background disparity in prevalence of traditional CVD risk factors, it is also likely that differential access to antiretroviral treatment, the younger age of the HIV-infected population, and types of antiretroviral treatment commonly used in LMICs contribute to the observed differences. SUMMARY: Overall, the state of evidence for CVD in LMICs is limited and at times contradictory. We summarize the evidence with suggestions for high priorities for further scientific investigation. Now is the crucial time to intervene in modifying CVD risk in LMICs.


Assuntos
Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/fisiopatologia , Infecções por HIV/complicações , Adulto , Antirretrovirais/uso terapêutico , Criança , Países em Desenvolvimento , Infecções por HIV/tratamento farmacológico , Acessibilidade aos Serviços de Saúde , Humanos , Medição de Risco
14.
Am Heart J ; 188: 175-185, 2017 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-28577673

RESUMO

BACKGROUND: Cardiovascular disease (CVD) is the leading cause of mortality worldwide, with >80% of CVD deaths occurring in low and middle income countries (LMICs). Diabetes mellitus and pre-diabetes are risk factors for CVD, and CVD is the major cause of morbidity and mortality among individuals with DM. There is a critical period now during which reducing CVD risk among individuals with diabetes and pre-diabetes may have a major impact. Cost-effective, culturally appropriate, and context-specific approaches are required. Two promising strategies to improve health outcomes are group medical visits and microfinance. METHODS/DESIGN: This study tests whether group medical visits integrated into microfinance groups are effective and cost-effective in reducing CVD risk among individuals with diabetes or at increased risk for diabetes in western Kenya. An initial phase of qualitative inquiry will assess contextual factors, facilitators, and barriers that may impact integration of group medical visits and microfinance for CVD risk reduction. Subsequently, we will conduct a four-arm cluster randomized trial comparing: (1) usual clinical care, (2) usual clinical care plus microfinance groups only, (3) group medical visits only, and (4) group medical visits integrated into microfinance groups. The primary outcome measure will be 1-year change in systolic blood pressure, and a key secondary outcome measure is 1-year change in overall CVD risk as measured by the QRISK2 score. We will conduct mediation analysis to evaluate the influence of changes in social network characteristics on intervention outcomes, as well as moderation analysis to evaluate the influence of baseline social network characteristics on effectiveness of the interventions. Cost-effectiveness analysis will be conducted in terms of cost per unit change in systolic blood pressure, percent change in CVD risk score, and per disability-adjusted life year saved. DISCUSSION: This study will provide evidence regarding effectiveness and cost-effectiveness of interventions to reduce CVD risk. We aim to produce generalizable methods and results that can provide a model for adoption in low-resource settings worldwide.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Países em Desenvolvimento , Diabetes Mellitus/terapia , Promoção da Saúde/métodos , Renda , Prevenção Primária/métodos , Comportamento de Redução do Risco , Adulto , Doenças Cardiovasculares/epidemiologia , Doenças Cardiovasculares/etiologia , Análise Custo-Benefício , Diabetes Mellitus/epidemiologia , Feminino , Seguimentos , Humanos , Incidência , Quênia/epidemiologia , Masculino , Estudos Retrospectivos , Fatores de Risco , Adulto Jovem
16.
Curr Cardiol Rep ; 18(10): 96, 2016 10.
Artigo em Inglês | MEDLINE | ID: mdl-27566329

RESUMO

Rheumatic heart disease (RHD) is a chronic valvular disease resulting after severe or repetitive episodes of acute rheumatic fever (ARF), an autoimmune response to group A Streptococcus infection. RHD has been almost eliminated with improved social and health infrastructure in affluent countries while it remains a neglected disease with major cause of morbidity and mortality in many low- and middle-income countries, and resource-limited regions of high-income countries. Despite our evolving understanding of the pathogenesis of RHD, there have not been any significant advances to prevent or halt progression of disease in recent history. Long-term penicillin-based treatment and surgery remain the backbone of a RHD control program in the absence of an effective vaccine. The advent of echocardiographic screening algorithms has improved the accuracy of diagnosing RHD and has shed light on the enormous burden of disease. Encouragingly, this has led to a rekindled commitment from researchers in the most affected countries to advocate and take bold actions to end this disease of social inequality.


Assuntos
Antibacterianos/uso terapêutico , Procedimentos Cirúrgicos Cardíacos/estatística & dados numéricos , Penicilina G Benzatina/uso terapêutico , Prevenção Primária/organização & administração , Cardiopatia Reumática/prevenção & controle , Prevenção Secundária/organização & administração , Streptococcus pyogenes/patogenicidade , Antibacterianos/provisão & distribuição , Países em Desenvolvimento , Progressão da Doença , Fidelidade a Diretrizes , Prioridades em Saúde , Necessidades e Demandas de Serviços de Saúde , Humanos , Doenças Negligenciadas , Penicilina G Benzatina/provisão & distribuição , Guias de Prática Clínica como Assunto , Melhoria de Qualidade , Cardiopatia Reumática/diagnóstico , Cardiopatia Reumática/epidemiologia
18.
Glob Heart ; 10(4): 313-7, 2015 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-26704963

RESUMO

Cardiovascular disease (CVD) is the leading cause of death in the world, with a substantial health and economic burden confronted by low- and middle-income countries. In low-income countries such as Kenya, there exists a double burden of communicable and noncommunicable diseases, and the CVD profile includes many nonatherosclerotic entities. Socio-politico-economic realities present challenges to CVD prevention in Kenya, including poverty, low national spending on health, significant out-of-pocket health expenditures, and limited outpatient health insurance. In addition, the health infrastructure is characterized by insufficient human resources for health, medication stock-outs, and lack of facilities and equipment. Within this socio-politico-economic reality, contextually appropriate programs for CVD prevention need to be developed. We describe our experience from western Kenya, where we have engaged the entire care cascade across all levels of the health system, in order to improve access to high-quality, comprehensive, coordinated, and sustainable care for CVD and CVD risk factors. We report on several initiatives: 1) population-wide screening for hypertension and diabetes; 2) engagement of community resources and governance structures; 3) geographic decentralization of care services; 4) task redistribution to more efficiently use of available human resources for health; 5) ensuring a consistent supply of essential medicines; 6) improving physical infrastructure of rural health facilities; 7) developing an integrated health record; and 8) mobile health (mHealth) initiatives to provide clinical decision support and record-keeping functions. Although several challenges remain, there currently exists a critical window of opportunity to establish systems of care and prevention that can alter the trajectory of CVD in low-resource settings.


Assuntos
Doenças Cardiovasculares/prevenção & controle , Prevenção Secundária/organização & administração , Assistência Ambulatorial , Doenças Cardiovasculares/epidemiologia , Efeitos Psicossociais da Doença , Atenção à Saúde/organização & administração , Objetivos , Acessibilidade aos Serviços de Saúde/organização & administração , Humanos , Quênia/epidemiologia , Área Carente de Assistência Médica
19.
Arq Bras Cardiol ; 104(1): 5-15, 2015 Jan.
Artigo em Inglês, Português | MEDLINE | ID: mdl-25714407

RESUMO

BACKGROUND: Cardiovascular research publications seem to be increasing in Latin America overall. OBJECTIVE: To analyze trends in cardiovascular publications and their citations from countries in Latin America between 1999 and 2008, and to compare them with those from the rest of the countries. METHODS: We retrieved references of cardiovascular publications between 1999 and 2008 and their five-year post-publication citations from the Web of Knowledge database. For countries in Latin America, we calculated the total number of publications and their citation indices (total citations divided by number of publications) by year. We analyzed trends on publications and citation indices over time using Poisson regression models. The analysis was repeated for Latin America as a region, and compared with that for the rest of the countries grouped according to economic development. RESULTS: Brazil (n = 6,132) had the highest number of publications in 1999-2008, followed by Argentina (n = 1,686), Mexico (n = 1,368) and Chile (n = 874). Most countries showed an increase in publications over time, leaded by Guatemala (36.5% annually [95%CI: 16.7%-59.7%]), Colombia (22.1% [16.3%-28.2%]), Costa Rica (18.1% [8.1%-28.9%]) and Brazil (17.9% [16.9%-19.1%]). However, trends on citation indices varied widely (from -33.8% to 28.4%). From 1999 to 2008, cardiovascular publications of Latin America increased by 12.9% (12.1%-13.5%) annually. However, the citation indices of Latin America increased 1.5% (1.3%-1.7%) annually, a lower increase than those of all other country groups analyzed. CONCLUSIONS: Although the number of cardiovascular publications of Latin America increased from 1999 to 2008, trends on citation indices suggest they may have had a relatively low impact on the research field, stressing the importance of considering quality and dissemination on local research policies.


Assuntos
Bibliometria , Pesquisa Biomédica/estatística & dados numéricos , Cardiologia/estatística & dados numéricos , Publicações Periódicas como Assunto/estatística & dados numéricos , Pesquisa Biomédica/tendências , Cardiologia/tendências , América Latina , Distribuição de Poisson , Fatores de Tempo
20.
Arq. bras. cardiol ; 104(1): 5-14, 01/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-741132

RESUMO

Background: Cardiovascular research publications seem to be increasing in Latin America overall. Objective: To analyze trends in cardiovascular publications and their citations from countries in Latin America between 1999 and 2008, and to compare them with those from the rest of the countries. Methods: We retrieved references of cardiovascular publications between 1999 and 2008 and their five-year post-publication citations from the Web of Knowledge database. For countries in Latin America, we calculated the total number of publications and their citation indices (total citations divided by number of publications) by year. We analyzed trends on publications and citation indices over time using Poisson regression models. The analysis was repeated for Latin America as a region, and compared with that for the rest of the countries grouped according to economic development. Results: Brazil (n = 6,132) had the highest number of publications in1999-2008, followed by Argentina (n = 1,686), Mexico (n = 1,368) and Chile (n = 874). Most countries showed an increase in publications over time, leaded by Guatemala (36.5% annually [95%CI: 16.7%-59.7%]), Colombia (22.1% [16.3%-28.2%]), Costa Rica (18.1% [8.1%-28.9%]) and Brazil (17.9% [16.9%-19.1%]). However, trends on citation indices varied widely (from -33.8% to 28.4%). From 1999 to 2008, cardiovascular publications of Latin America increased by 12.9% (12.1%-13.5%) annually. However, the citation indices of Latin America increased 1.5% (1.3%-1.7%) annually, a lower increase than those of all other country groups analyzed. Conclusions: Although the number of cardiovascular publications of Latin America increased from 1999 to 2008, trends on citation indices suggest they may have had a relatively low impact on the research field, stressing the importance of considering quality and dissemination on local research policies. .


Fundamento: As publicações sobre pesquisa cardiovascular parecem estar crescendo na América Latina em geral. Objetivo: Analisar as tendências nas publicações cardiovasculares e suas citações de países na América Latina entre 1999 e 2008, e compará-las àquelas dos demais países. Métodos: Recuperamos, a partir da base de dados Web of Knowledge, as referências de publicações cardiovasculares entre 1999 e 2008 e as suas citações cinco anos após publicação. Para os países da América Latina, calculamos o número total de publicações e seus índices de citação (número total de citações dividido pelo número de publicações) por ano. Analisamos as tendências das publicações e dos índices de citação ao longo do tempo usando modelos de regressão de Poisson. A análise foi repetida para a América Latina como região e comparada àquela para os demais países agrupados de acordo com o desenvolvimento econômico. Resultados: O Brasil (n = 6.132) apresentou o mais alto número de publicações no período 1999-2008, seguindo-se Argentina (n = 1.686), México (n = 1.368) e Chile (n = 874). A maioria dos países apresentou elevação do número de publicações ao longo do tempo, principalmente Guatemala (36,5% anual [IC 95%: 16,7%-59,7%]), Colômbia (22,1% [16,3%-28,2%]), Costa Rica (18,1% [8,1%-28,9%]) e Brasil (17,9% [16,9%-19,1%]). No entanto, as tendências dos índices de citação variaram muito, de -33,8% a 28,4%. De 1999 a 2008, as publicações cardiovasculares na América Latina aumentaram em 12,9% (12,1%-13,5%) por ano. Entretanto, os índices de citação da América Latina aumentaram 1,5% (1,3%-1,7%) por ano, um aumento menor do que aqueles dos demais grupos de países analisados. Conclusões: Embora o número de publicações cardiovasculares da América Latina tenha aumentado de 1999 a 2008, tendências nos índices de citação sugerem que elas possam ter tido um impacto relativamente baixo na área de pesquisa, reforçando a importância de se considerar a qualidade e a disseminação ...


Assuntos
Bibliometria , Pesquisa Biomédica/estatística & dados numéricos , Cardiologia/estatística & dados numéricos , Publicações Periódicas como Assunto/estatística & dados numéricos , Pesquisa Biomédica/tendências , Cardiologia/tendências , América Latina , Distribuição de Poisson , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA